Life Sciences Tools and Services
Company Overview of Accelovance, Inc.
Accelovance, Inc., a contract research organization (CRO), provides site management organization, patient recruitment, and clinical call center services. The company focuses on oncology, vaccines, and general medicine to pharmaceutical and biotech industries. Its CRO services include protocol development, project management, clinical trial monitoring, data management, biostatistics, pharmacovigilance, regulatory affairs, and medical writing services. The company also provides clinical call center services, such as recruitment/retention/compliance, post approval safety studies, phase IV studies, surveillance programs, patient-reported outcomes, observational studies, registries, site support ...
2275 Research Boulevard
Rockville, MD 20850
Founded in 2004
Key Executives for Accelovance, Inc.
Founder, Chief Executive Officer and President
Managing Director of Accelovance China
Managing Executive Director of Accelovance Europe
Compensation as of Fiscal Year 2016.
Accelovance, Inc. Key Developments
Accelovance, Inc. and FHI 360 Enters into Strategic Alliance
Nov 3 15
Accelovance, Inc. and FHI 360 entered into a strategic alliance to more comprehensively serve the international drug development research efforts of pharmaceutical, governmental, and nonprofit organizations. The strategic alliance expands Accelovance's service offering and capabilities in developing countries in Africa, Asia Pacific, and South America, and expands FHI's capabilities and coverage in North America and Europe. Both CRO’s have been collaborating on projects in several regions of the world, most notably on a large Phase III Ebola vaccine trial in Sierra Leone. This strategic alliance enables both companies to expand their global footprint and support the full program drug development needs of pharmaceutical, governmental, and nonprofit organizations.
Accelovance, Inc. Appoints Mark S. Gelder as Vice President of Medical Affairs, Oncology
Sep 30 15
Accelovance, Inc. announced that Mark S. Gelder has joined the company as Vice President Medical Affairs, Oncology. Gelder brings more than 25 years of oncology clinical trial and drug development experience to the company, having provided significant contributions in the investigation, approval, and postmarketing development of multiple products.
Midwest Melanoma Partnership and Accelovance, Inc. Enhance Melanoma Research Offering Through Strategic Alliance
Sep 15 15
Accelovance, Inc. and the Midwest Melanoma Partnership have entered into a strategic alliance to enhance the research and advancement of treatment options for patients suffering from melanoma. The strategic alliance provides pharmaceutical and biotechnology companies with enhanced access to melanoma key opinion leaders, expedited contracting and protocol review within MMP's 19 academic and community-based research center members, and Accelovance's oncology-experienced clinical and project staff within the United States and Europe.
Similar Private Companies By Industry
Recent Private Companies Transactions